AstraZeneca pins bone disease drug’s Phase III failure on high placebo response
AstraZeneca’s enzyme replacement therapy (ERT) candidate, efzimfotase alfa, has failed to demonstrate significant benefits over placebo in a late-stage trial …
Post
-
-
Lilly reports Phase IIIb data on Taltz and Zepbound combination
Eli Lilly and Company has reported exploratory Phase IIIb trial results showing that combining Taltz and Zepbound alters more immune …
-
Perceive Bio concludes Phase IIa trial enrolment for GA
Perceive Biotherapeutics (Perceive Bio) has concluded enrolment ahead of targets in its Phase IIa JOURNEY clinical study evaluating VOY-101, an …
-
Alumis snags set of Phase III psoriasis pill victories, but analysts lukewarm on impact
California-based biopharma company Alumis has debuted data from a trio of Phase III studies that the company says highlights the …
-
EU clinical trial advice pilot becomes permanent
The European Medicines Agency (EMA) is permanently putting its Accelerating Clinical Trials in the EU (ACT EU) pilot into practice. The …
-
Alumis snags set of Phase III psoriasis pill victories, but analysts lukewarm on impact
California-based biopharma company Alumis has debuted data from a trio of Phase III studies that the company says highlights the …
-
EU clinical trial advice pilot becomes permanent
The European Medicines Agency (EMA) is permanently putting its Accelerating Clinical Trials in the EU (ACT EU) pilot into practice. The …
-
Endeavor’s Phase IIb IPF study of taladegib meets endpoints
Endeavor BioMedicines has reported that its Phase IIb WHISTLE-PF clinical trial assessing taladegib (ENV-101) achieved its primary and several key …
-
Schizophrenia research grapples with trial design hurdles in hunt for new treatments
Placebo response in acute schizophrenia trials has been rising for decades. At the same time, the observed treatment benefit is …
-
Alpheus begins multi-centre study for butterfly GBM
Alpheus Medical has begun the multi-centre Butterfly study to assess its investigational Porphyrin Metabolite Activation (PoMA) therapy in patients with …
-
Alzheimer’s disease market expected to reach $14.7bn across the 8MM by 2033
The Alzheimer’s disease market is expected to grow at a high compound annual growth rate (CAGR) of 20.0% from $2.4 …
-
BMS’s Zenbexus meets PFS endpoint in pivotal multiple myeloma trial
Bristol Myers Squibb’s (BMS’s) Phase III trial of Zenbexus (iberdomide) has more than doubled progression-free survival (PFS) in patients with …
-
MimiVax announces disappointing pivotal Phase IIb trial data for cancer vaccine
The pivotal SURVIVE Phase IIb trial for SurVaxM, a glioblastoma (GBM) peptide-mimic immunotherapeutic cancer vaccine developed by MimiVax, announced interesting …
-
Argenx cans Phase III Vyvgart Sjögren’s study on predicted efficacy fail
Argenx has terminated a late-stage trial evaluating its marketed therapy, Vyvgart Hytrulo (efgartigimod alfa, hyaluronidase-qvfc) in Sjögren's syndrome – dashing …
-
Lantern Pharma secures Taiwan clearances for Phase II NSCLC study
Lantern Pharma has secured regulatory and Institutional Review Board (IRB) clearances in Taiwan to initiate Part 2 of its Phase …
